colorectal cancer
Conditions
Interventions
Olanzapine
5mg PO on days 1 to 4 Aprepitant
125 mg PO on day 1, 80 mg PO on days 2 to 3 5HT3-receptor antagonist
IV administration on day 1 Dexamethasone
6.6 mg IV on day 1, 4 mg PO on days 2 to 3
Sponsors
Osaka International Cancer Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Oxaliplatin-naive patients who receive the oxaliplatin (>=85mg/m2)-based chemotherapy 2. no limitation in TNM stage, recurrence, or metastatic unresectable. 3. no limitation of use of targeted therapy 4. Enough organ functions 5. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Patients who has severe dysfunction of liver or kidney 2. Patients who suffered nausea or vomiting before 24 h of the enrollment 3. Patients who used antiemetics before 24 h of the enrollment 4. Patients with symptomatic brain metastasis/carcinomatosis. 5. Patients who had diabetes. 6. Pregnant, breastfeeding or expecting woman. 7. Patient is receiving pimozide 8. Patient is judged inappropriate by the investigator as subject for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of adverse events | — |
Countries
Japan
Contacts
Public ContactJunichi Nishimura
Osaka International Cancer Institute Department of Gastroenterological surgery
Outcome results
None listed